Major depressive disorder (MDD) is the leading cause of disability worldwide and reduces
life expectancy. Achieving and sustaining remission from depression is challenging after …

Background Ketamine rapidly improves depressive symptoms in patients with treatment-
resistant major depressive disorder (MDD) who do not respond to multiple standard …

Growing evidence of the rapid antidepressant effects of ketamine represents a promising
advance in treatment-resistant depression (TRD) therapeutics. Most studies provide …

Existing treatments for major depressive disorder (MDD) usually take weeks to months to
achieve their antidepressant effects, and a significant number of patients do not have …

Over a third of patients with major depressive disorder (MDD) do not have an adequate
response to first-line antidepressant treatments, ie, they have treatment-resistant depression …

Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA
receptor antagonist, to induce rapid (within hours), transient antidepressant effects when …

Objective Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has
shown rapid antidepressant effects, but small study groups and inadequate control …

Although conventional oral antidepressants are effective in patients with major depressive
disorder (MDD), up to 30% of these patients do not achieve symptomatic remission, even …

Depression is a common psychiatric disorder affecting more than 300 million people
worldwide. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth …

Background Ketamine is reported to have rapid antidepressant effects; however, there is
limited understanding of the time-course of ketamine effects beyond a single infusion. A …